Rallis India (RALLIS) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 revenue was ₹522 Cr, down from ₹598 Cr year-over-year, mainly due to a 38% decline in export business volumes and pricing pressure; nine-month revenue at ₹2,233 Cr, slightly up from ₹2,212 Cr year-over-year.

• Net profit for Q3 FY25 stood at ₹19 Cr, compared to ₹30 Cr in Q3 FY24; nine-month net profit at ₹143 Cr, up from ₹30 Cr in the prior year period.

• EBITDA for Q3 FY25 dropped 27% year-over-year, mainly from volume declines and pricing pressure in exports; PAT fell 56% year-over-year.

• Domestic agrochemical business saw volume growth despite intense competition and price corrections, with herbicides and biologicals showing strong momentum.

• Portfolio rationalization is complete, with focus shifting to higher-margin products and reducing the long tail of SKUs.

Financial highlights

• Total income for Q3 FY25 was ₹528 Cr, compared to ₹600 Cr in Q3 FY24; total expenses for Q3 FY25 were ₹509 Cr, down from ₹570 Cr in Q3 FY24.

• Domestic revenue was INR 492 crore, with biological and specialty solutions growing 13% in Q3 and 24% YTD.

• Export revenue was INR 110 crore, reflecting continued headwinds from global oversupply and pricing pressure; Q3 export volumes fell 34% year-over-year, revenue down 38%.

• Gross margin improved by 300-350 basis points, driven by product mix, inventory management, and cost efficiencies.

• Basic and diluted EPS for Q3 FY25 was ₹1.25, compared to ₹1.57 in Q3 FY24; EPS for nine months FY25 at ₹7.61, up from ₹1.25 in the prior year period.

Outlook and guidance

• No formal forward guidance provided; management remains cautiously optimistic for Q4, focusing on capacity utilization and market share improvement.

• Strategic focus on expanding product and customer portfolios, especially in Custom Synthesis Manufacturing (CSM) and Biologicals & Specialty Solutions (BSS).

• Emphasis on digital transformation, R&D, and sustainability initiatives aligned with Tata Group's goals.

• Domestic demand expected to remain stable, but pricing pressure and inventory overhang persist; export market outlook remains weak for 2025, especially in the Americas, due to low commodity prices and Chinese overcapacity.

• Business performance is seasonal and can be impacted by weather and cropping patterns.